Skip to content

Study · Randomized controlled trial · 2026

6 results

People With Lowest Physical Functioning Scores Showed Greatest Improvement After Tirzepatide Treatment.

Li X, Cao D, Sapin H, Wang F, Hunter Gibble T, Raibulet NK, Denning M, Kaplan LM

Obesity (Silver Spring, Md.)4 Nov 2025Cited by 2 (Europe PMC)

PMID41187013 (opens in a new tab)PMCIDPMC12724063 (opens in a new tab)DOI10.1002/oby.70067 (opens in a new tab)PepBankPUB-41187013
Download PDFPubMedAsk about this study
Jump to 6 results

Summary

ObjectiveThis post hoc analysis of SURMOUNT trials assessed the association of baseline physical function (PF) with obesity-related complications (ORCs), efficacy measures, and PF. The mechanism of tirzepatide-led improvements in PF was evaluated.MethodsOutcomes were assessed among participants (SURMOUNT-1 = 2539; SURMOUNT-3 = 579; SURMOUNT-4 = 670) grouped by baseline quartiles (Q) of SF-36v2 PF scores within study (higher scores = better PF). Least-squares mean changes from baseline in efficacy measures and PF were estimated using ANCOVA. Pearson's correlation between weight reduction and improvement in PF was calculated.ResultsIn SURMOUNT-1, participants with lower baseline PF had more ORCs. Tirzepatide-treated participants showed similar reductions in weight (kg; -20.1% to -22.8%), waist circumference (-17.2 to -20.2 cm), and BMI (-7.2 to -9.0 kg/m2) across quartiles. Participants with lower baseline PF reported greater improvements in PF with tirzepatide (Q1 = 12.5; Q4 = -0.8). Results were similar in SURMOUNT-3 and SURMOUNT-4. A weak to mild correlation was noted between weight reduction and improved PF; the strength of correlation decreased from Q1 to Q4.ConclusionsLower baseline PF was associated with a higher prevalence of ORCs. Patients taking tirzepatide experienced substantial weight loss, regardless of their baseline PF. Tirzepatide may improve PF through both weight loss-dependent and -independent mechanisms, especially in those with lower baseline PF.Trial registrationClinicalTrials.gov identifiers: SURMOUNT-1, NCT04184622; SURMOUNT-3, NCT04657016; SURMOUNT-4, NCT04660643.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In adults with obesity in SURMOUNT-1, tirzepatide reduced weight by 20.1% to 22.8%, similar across baseline physical function quartiles.

    In plain wordsIn adults with obesity, tirzepatide reduced weight by a similar amount whatever their starting physical function.

    Peptide
    Tirzepatide
    Outcome
    DecreaseWeight change across baseline physical function quartiles
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    weight change
    −20.1 to −22.8%
    across quartiles

    Source sentences

    Summary
    Tirzepatide-treated participants showed similar reductions in weight (kg; -20.1% to -22.8%)
    1 context sentence
    Summary · context
    Outcomes were assessed among participants (SURMOUNT-1 = 2539; SURMOUNT-3 = 579; SURMOUNT-4 = 670) grouped by baseline quartiles (Q) of SF-36v2 PF scores within study (higher scores = better PF).
  2. 02HumanRandomized controlled trialEfficacy outcome

    In adults with obesity in SURMOUNT-1, tirzepatide reduced waist circumference by 17.2 to 20.2 cm, similar across baseline physical function quartiles.

    In plain wordsIn adults with obesity, tirzepatide reduced waist size by a similar amount whatever their starting physical function.

    Peptide
    Tirzepatide
    Outcome
    DecreaseWaist circumference change across baseline physical function quartiles
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    waist circumference change
    −17.2 to −20.2 cm
    across quartiles

    Source sentences

    Summary
    waist circumference (-17.2 to -20.2 cm)
    1 context sentence
    Summary · context
    Outcomes were assessed among participants (SURMOUNT-1 = 2539; SURMOUNT-3 = 579; SURMOUNT-4 = 670) grouped by baseline quartiles (Q) of SF-36v2 PF scores within study (higher scores = better PF).
  3. 03HumanRandomized controlled trialEfficacy outcome

    In adults with obesity in SURMOUNT-1, tirzepatide reduced BMI by 7.2 to 9.0 kg/m2, similar across baseline physical function quartiles.

    In plain wordsIn adults with obesity, tirzepatide reduced BMI by a similar amount whatever their starting physical function.

    Peptide
    Tirzepatide
    Outcome
    DecreaseBMI change across baseline physical function quartiles
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    BMI change
    −7.2 to −9 kg/m2
    across quartiles

    Source sentences

    Summary
    and BMI (-7.2 to -9.0 kg/m2) across quartiles
    1 context sentence
    Summary · context
    Outcomes were assessed among participants (SURMOUNT-1 = 2539; SURMOUNT-3 = 579; SURMOUNT-4 = 670) grouped by baseline quartiles (Q) of SF-36v2 PF scores within study (higher scores = better PF).
  4. 04HumanRandomized controlled trialEfficacy outcome

    In SURMOUNT-1, participants with lower baseline physical function reported greater improvements in physical function with tirzepatide (Q1 = 12.5; Q4 = -0.8).

    In plain wordsIn adults with obesity, those with the lowest starting physical function improved most on tirzepatide.

    Peptide
    Tirzepatide
    Outcome
    IncreaseSF-36v2 physical function change by baseline quartile
    Study

    n: not reported in source

    Comparator
    Baseline physical function quartile
    Outcome group
    Exercise and physical function · Whole body
    Studied dose
    Dose not stated

    Measurements

    PF change
    12.5 points
    Q1
    PF change
    −0.8 points
    Q4

    Source sentences

    Summary
    Participants with lower baseline PF reported greater improvements in PF with tirzepatide (Q1 = 12.5; Q4 = -0.8).
    1 context sentence
    Summary · context
    Outcomes were assessed among participants (SURMOUNT-1 = 2539; SURMOUNT-3 = 579; SURMOUNT-4 = 670) grouped by baseline quartiles (Q) of SF-36v2 PF scores within study (higher scores = better PF).
  5. 05HumanRandomized controlled trialEfficacy outcome

    In SURMOUNT-3 and SURMOUNT-4, the results for weight and physical function by baseline quartile were similar to those in SURMOUNT-1.

    In plain wordsIn two more tirzepatide trials, results were similar: lower starting physical function went with greater improvement.

    Peptide
    Tirzepatide
    Outcome
    IncreasePhysical function change in SURMOUNT-3 and SURMOUNT-4
    Study

    n: not reported in source

    Comparator
    Baseline physical function quartile
    Outcome group
    Exercise and physical function · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Results were similar in SURMOUNT-3 and SURMOUNT-4.
    1 context sentence
    Summary · context
    Outcomes were assessed among participants (SURMOUNT-1 = 2539; SURMOUNT-3 = 579; SURMOUNT-4 = 670) grouped by baseline quartiles (Q) of SF-36v2 PF scores within study (higher scores = better PF).
  6. 06HumanRandomized controlled trialMechanism

    In tirzepatide-treated adults, a weak to mild correlation was noted between weight reduction and improved physical function, and it decreased from Q1 to Q4.

    In plain wordsIn adults on tirzepatide, weight loss was only weakly linked to better physical function, less so at higher starting function.

    Peptide
    Tirzepatide
    Outcome
    Not applicableCorrelation of weight reduction with physical function improvement
    Study

    n: not reported in source

    Outcome group
    Exercise and physical function · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    A weak to mild correlation was noted between weight reduction and improved PF; the strength of correlation decreased from Q1 to Q4.
    1 context sentence
    Summary · context
    Outcomes were assessed among participants (SURMOUNT-1 = 2539; SURMOUNT-3 = 579; SURMOUNT-4 = 670) grouped by baseline quartiles (Q) of SF-36v2 PF scores within study (higher scores = better PF).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials3

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

3 trials · 3 completed · 3 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT04657016

A Study of Tirzepatide (LY3298176) In Participants After A Lifestyle Weight Loss Program

Eli Lilly and Companyn = 57929 Mar 2021 to 12 May 2023

Obesity · Overweight

Trial pageClinicalTrials.govUpdated 16 May 2024
CompletedPhase 3Results postedNCT04660643

A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight for the Maintenance of Weight Loss

Eli Lilly and Companyn = 78329 Mar 2021 to 18 May 2023

Obesity · Overweight

Trial pageClinicalTrials.govUpdated 22 May 2024
CompletedPhase 3Results postedNCT04184622

A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight

Eli Lilly and Companyn = 2,5394 Dec 2019 to 6 Jul 2024

Overweight · Obesity

Trial pageClinicalTrials.govUpdated 24 Jul 2025

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:07 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.